A Phase Iii Prospective Active And Placebo-Controlled Randomized Trial Of Vilazodone In The Treatment Of Major Depressive Disorder

BackgroundDepression is a leading cause of psychiatric morbidity in the modern world, and the introduction of selective serotonin reuptake inhibitors (SSR1s) is a revolution in the treatment of depression. Vilazodone, a novel SSRI and 5-HT1A partial agonist, received FDA approval in 2011 to treat the major depressive disorder (MDD) in adults. This study conducted in India aimed to evaluate the efficacy and safety of vilazodone when compared to escitalopram or placebo in patients with MDD.MethodsThis was a prospective, multicentre, randomized, comparative study of 375 participants over eight weeks of treatment with either vilazodone (10-40mg/day) or escitalopram (10-40 mg/day) or placebo in adult patients with MDD. Primary efficacy was assessed using the Hamilton Rating Scale for Depression (HAM-D-17); secondary efficacy was assessed using the Mon tgomery-Asherg Depression Rating Scale (MADRS) score and Hamilton Anxiety Scale (HAM-A) score. Safety parameters included adverse events (AEs), clinical laboratory results, vital signs, electrocardiogram ( ECG), and Columbia-Suicide Severity Rating Scale (C-SSRS).ResultsMean change in the HAM-I)-17 total score from baseline to week 8 For vilazodone, escitalopram, and placebo-treated patients in intent-to-treat (TIT) population was: -18.9 (+/- 7.49), -17.8 (+/- 6.06), and -7.4 (+/- 6.32); in ITT population (with Last Observation Carried Forward( LOCF) imputation) was: -17.9 (+/- 7.71), 17.4 (+/- 6.19), and -6.4 (+/- 6.84), and in per-protocol (PP) population was: -19.1 (+/- 7.20), -17.8 (+/- 6.08), and -7.7 (+/- 6.29), respectively. The upper limit of 95% CI (0.56 (ITT); 0.90 (ITT with LOCF Imputation); 0.23 (PP)) of difference in HAM-D-17 between vilazodone 40mg and escitalopram 40mg, which is lower than the defined non-inferiority margin (3.56), proving non-inferiority. The difference between vilazodone 40mg, escitalopram 40mg, and the placebo was statistically significant (p<0.0001). No deaths or serious adverse events were reported in this study.ConclusionVilazodone demonstrated comparable efficacy to escitalopram and superior efficacy over the placebo in the treatment of MDD.